Form 4: Kronos Bio Director Divests All Holdings Following Concentra Biosciences Merger

David M. Tanen, a Director of Kronos Bio, Inc., has reported the complete disposition of his direct and indirect common stock and stock option holdings in connection with the company's acquisition by Concentra Biosciences.

Summary

• David M. Tanen, a Director of Kronos Bio, Inc., disposed of all his beneficial ownership in the company's common stock and stock options on June 20, 2025.
• This disposition occurred as a result of the merger between Kronos Bio, Inc. and Concentra Merger Sub IV, Inc., a wholly-owned subsidiary of Concentra Biosciences, LLC, which completed its tender offer on June 18, 2025.
• The merger consideration for outstanding shares of Kronos Bio common stock was $0.57 per share in cash (the 'Cash Amount') plus one non-transferable contractual contingent value right (CVR).
• Mr. Tanen disposed of a total of 913,783 shares of common stock, including 363,428 directly held shares and 550,355 indirectly held shares (via the David Tanen Revocable Grantor Trust and holdings by his son and daughter), all at the $0.57 per share cash price.
• All 228,100 outstanding stock options held by Mr. Tanen became fully vested and exercisable immediately prior to the merger's effective time.
• These options were subsequently cancelled and converted into the right to receive one CVR for each underlying share; however, no cash consideration was received for the options themselves, as their exercise prices (ranging from $0.95 to $24.18) were all greater than the $0.57 cash offer price per share.
• Following these transactions, Mr. Tanen's beneficial ownership in Kronos Bio, Inc. is 0 shares of common stock and 0 derivative securities, though he holds the CVRs received from both shares and options.

Sentiment

Score: 3

Explanation: The sentiment is negative for the reporting person's equity holdings as all options were out-of-the-money relative to the cash offer price, resulting in no cash payout for them. While common stock received cash plus CVRs, the overall outcome for the director's equity compensation appears unfavorable based on the option exercise prices.

Positives

• The merger provides immediate liquidity to shareholders, including the reporting person, for their common stock at a fixed cash price of $0.57 per share.
• Shareholders also receive a Contingent Value Right (CVR) for each share and underlying option, offering potential future upside based on specific milestones or events, which could provide additional value.
• The completion of the acquisition provides certainty regarding the company's future structure and ownership under Concentra Biosciences.

Negatives

• The cash offer price of $0.57 per share is significantly lower than the exercise prices of all stock options held by Mr. Tanen (ranging from $0.95 to $24.18), resulting in no cash payout for these options.
• The value of the Contingent Value Rights (CVRs) is contingent and uncertain, dependent on future events, which introduces risk regarding the reporting person's potential future returns from the options.
• The reporting person, a director, has completely divested his equity stake in the company, indicating a full exit from direct ownership.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on future events, which may or may not materialize, potentially resulting in no additional payout beyond the initial cash consideration.
• The cash consideration of $0.57 per share is relatively low, especially when compared to the exercise prices of the disposed stock options, indicating a significant decline in the company's valuation prior to the merger.

Future Outlook

The document indicates the completion of the merger, with Kronos Bio, Inc. becoming a wholly-owned subsidiary of Concentra Biosciences, LLC. The future outlook for former shareholders now holding CVRs is dependent on the terms and milestones outlined in the Contingent Value Rights Agreement, which are not detailed in this filing.

Industry Context

This Form 4 filing reflects the final stages of an acquisition in the biotechnology or pharmaceutical sector, where a smaller company (Kronos Bio) is acquired by a larger entity (Concentra Biosciences). Such mergers are common in the industry, often driven by the acquiring company's interest in the target's pipeline, technology, or market position, and can provide an exit for investors in the acquired entity, albeit sometimes at a discount to prior valuations.

Comparison to Industry Standards

• Given this is a Form 4 detailing a director's disposition of shares post-merger, direct comparisons to industry-standard financial results or project outcomes are not applicable.
• The acquisition price of $0.57 per share, coupled with CVRs, suggests a valuation that may be below the initial public offering price or peak valuations for Kronos Bio, which is not uncommon for biotech companies that face clinical trial challenges or market shifts.
• Without specific details on the CVRs or the company's pipeline performance, a detailed comparison to similar biotech acquisitions (e.g., acquisition multiples, premium paid over pre-announcement share price) is not possible from this document alone.
• The cancellation of options with exercise prices significantly above the cash offer price is a common outcome in acquisitions where the target company's stock has declined.

Management Changes

Corporate Governance

Related Party Transactions

• The filing discloses the disposition of shares held indirectly by the David Tanen Revocable Grantor Trust and by his son and daughter, which are considered related party holdings, as part of the merger transaction.

Stakeholder Impact

• Shareholders (former): Received $0.57 per share in cash and one CVR for each share, providing liquidity and potential future upside from the CVRs.
• Employees (former): Employees holding stock options would have had their options converted to CVRs and potentially cash if their exercise price was below the cash offer, similar to the director.
• Company (Kronos Bio, Inc.): Now operates as a wholly-owned subsidiary of Concentra Biosciences, LLC, indicating a change in strategic direction and operational control.

Next Steps

• Former shareholders of Kronos Bio, Inc. will receive the cash consideration and CVRs as per the merger agreement.
• The future value of the CVRs will depend on the achievement of specific milestones or events as defined in the Contingent Value Rights Agreement.

Key Dates

Recommendation

Keywords

Kronos Bio, KRON, SEC Form 4, Insider Trading, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Stock Options, Beneficial Ownership, David M. Tanen, Concentra Biosciences